On December 26, 2019, during a glorious ceremony attended by more than 180 psychiatrists and neurologists, three new drugs of Actoverco Company were officially unveiled.

The ceremony began with a speech by Ms. Nahaleh Naraghi, CEO of Actoverco, followed by Dr. Jamal Shams (psychiatrist and faculty member of Shahid Beheshti University of Medical Sciences), Dr. Farhad Assarzadegan (neurologist and faculty member of Shahid Beheshti University of Medical Sciences) and Dr. Mohammad Arbabi (psychiatrist and faculty member of Tehran University of Medical Sciences and Roozbeh Hospital) gave a scientific lecture on the importance of these drugs and their therapeutic status.

Introduced drugs include a novel medication for the treatment of refractory depression (especially in patients that experience side effects with other antidepressants), treatment of epilepsy in people over 4 years of age and treatment of psychotic symptoms in patients with bipolar disorder and schizophrenia.

Actoverco Pharmaceutical Company has always tried to produce the best drugs with world quality and reasonable prices by providing the best raw materials and excipients of medicine, and using advanced laboratory and production facilities along with the scientific and technical knowledge of its specialists.

The drugs introduced at the event were provided with the Actoverco’s commitment to providing high-quality medicine and are now available to doctors and the public in pharmacies across the country.